Oxford Brain Diagnostics Partners with Memory Treatment Centers to Advance Alzheimer’s Research

Summary:
Oxford Brain Diagnostics (OBD) and Memory Treatment Centers (MTC) have formed a research collaboration to study Alzheimer’s disease in cognitively impaired patients undergoing anti-amyloid treatments. This partnership will leverage OBD’s Cortical Disarray Measurement (CDM®) technology to assess brain regions affected by neurodegeneration and monitor disease progression.

Technology and Study Details:
OBD’s CDM® technology analyzes changes in brain microstructure to quantify neurodegeneration, providing critical insights into Alzheimer’s progression. In collaboration with MTC, OBD will evaluate how CDM® can track cognitive decline in patients receiving anti-amyloid therapy. This research aims to deepen the understanding of how cortical microstructure impacts Alzheimer’s and treatment efficacy, contributing to improved diagnostic tools.

Synergy and Clinical Impact:
The partnership allows MTC to provide real-world, HIPAA-compliant data to support global Alzheimer’s research. Together, OBD and MTC aim to advance patient care by offering innovative diagnostic solutions, expanding the global knowledge base on Alzheimer’s, and exploring potential breakthroughs in treatment monitoring.